|
22 Sep 2015 |
Social |
OCTAVE studies shows tofacitinib 10 mg bid to be effective in treating moderate to severe ulcerative colitis http://t.co/MbdSUymAji |
|
|
16 Jan 2017 |
Social |
Baricitinib decision by the FDA extended from Jan 2017 by another 3 mos for FDA to review major amendment to NDA https://t.co/tMi3llwWZw |
|
|
08 Jun 2016 |
Social |
Is there enough data to support a non-TNFi biologic as the 1st choice? Dr. Janet Pope says the data clearly says so https://t.co/Ai5izsTDN8 |
|
|
09 May 2018 |
Social |
AbbVie Submits Biologics License Application to FDA for Risankizumab (IL-23 Mab) for Moderate to Severe Plaque Psoriasis https://t.co/4lq3xKc6T1 |
|
|
23 Oct 2018 |
Social |
RT @ArthurRheum: Another Adalimumab biosimilars is coming... similar efficacy and immunogenicity as original @RheumNow #ACR18 https://t.co/… |
|
|
25 Jul 2019 |
Social |
FDA has approved Ruxience (rituximab-pvvr; Pfizer), a biosimilar to Rituxan for use in NHL, CLL, granulomatosis w/ polyangiitis (GPA) & microscopic polyangiitis;(NOT RA) THis is the 2nd RTX biosimilar. https://t.co/GuVG6S980j |
|
|
23 Oct 2015 |
Social |
Pretreatment CRP or IL-6 levels are not predictive of responses to tocilizumab https://t.co/IOQGWOGGQA |
|
|
15 Feb 2017 |
Social |
Correction: Abbvies JAK inhibitor ABT-494) has a name, Uptacitinib, is currently in phIII trials. #RWCS 2017 info from Dr. M Genovese |
|
|
07 Nov 2017 |
Social |
RT @philipcrobinson: New Jak-1 selective inhibitor ABT-494 doesn’t look too bad #ACR17 @RheumNow https://t.co/sAHVqJr31a |
|
|
13 Jun 2018 |
Social |
RT @philipcrobinson: A phase IIB study of UCBs new anti-IL-17 drug bimekizumab that neutralises both IL17 A and F showed good results, can’… |
|
|
27 Nov 2015 |
Social |
RCT shows Hidradenitis suppurativa pts respond well to anakinra (esp after wk 8) w/ less IFN and increased IL-22 https://t.co/OfndT569gt |
|
|
23 May 2017 |
Social |
FDA approves Actemra as1st approved drug to treat Giant Cell Arteritis. See RheumNow report. https://t.co/73UieZpbn1 https://t.co/HjUzi0H6OL |
|
|
13 Mar 2017 |
Social |
Review of severe alopecia areata 90pts Rx w/ Xeljanz: 20% nearly total regrowth, 58% >50% regrowth,77% some regrowth https://t.co/8BZwOqevct |
|
|
12 Nov 2019 |
Social |
RT @uptoTate: Drs. Davila and Solow say “No good data to suggest that biologic DMARDs contribute to progression of MGUS so okay to treat as… |
|
|
17 Jun 2015 |
Social |
Metanalysis of 7 RCTs compares high vs low dose RTX in RA shows little clinical difference. Better Xray w/ high dose http://t.co/ySSo3gVKE8 |
|
|
25 Feb 2016 |
Social |
How to manage patients who worry, wont do & negatively inclined re:health/meds - the negative narrator in your head https://t.co/KEeVcWVedr |
|
|
06 Aug 2017 |
Social |
RheumNow Wk in Review is up! FDA hearings on sirukumab, tofacitinib. iTUNES, podcast https://t.co/rX1zLRHUuA & video https://t.co/slvfTJYR1E |
|
|
14 Apr 2017 |
Social |
How will new BIOSIMILAR biologic drugs affect PATIENTS - Make Your views count in a Patient survey; vote at>> https://t.co/ZhM9MiDCd7 |
|
|
16 Nov 2017 |
Social |
RT @VickiShanmugam: Biologic therapy is associated with decline in disease activity in #Hidradenitis suppurativa with greatest impact seen… |
|
|
31 Jul 2018 |
Social |
EMA's CHMP has recommended approval of the IL-23 inhibitor tildrakizumab (Ilumetri, Almirall) for adults with moderate - severe plaque psoriasis. (Based on reSURFACE1 and reSURFACE2 RCTs w/ >80% PASI 75 responses. https://t.co/Qm0qIgAJ2G |
|
